The use of prostate-specific antigen (PSA) has revolutionized the diagnostics of PCa during the past 25 years and more recently systematic PSA screening has been shown to decrease PCa-related mortality [4]. This evidence concerns the gene KLK3 and posterior cortical atrophy.